Profile data is unavailable for this security.
About the company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
- Revenue in CHF (TTM)74.12m
- Net income in CHF-296.43m
- Incorporated2017
- Employees938.00
- LocationIdorsia LtdHegenheimermattweg 91ALLSCHWIL 4123SwitzerlandCHE
- Websitehttps://www.idorsia.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innate Pharma SA | 23.14m | -31.71m | 115.51m | 168.00 | -- | 4.31 | -- | 4.99 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Cellectis SA | 32.22m | -93.25m | 116.50m | 235.00 | -- | 1.01 | -- | 3.62 | -1.41 | -1.11 | 0.4017 | 1.72 | 0.119 | -- | 6.23 | 147,226.70 | -35.11 | -24.08 | -53.69 | -30.69 | -- | -64.64 | -294.96 | -308.24 | -- | -2.77 | 0.452 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Adocia SA | 487.02k | -19.29m | 117.13m | 79.00 | -- | -- | -- | 240.51 | -1.53 | -1.53 | 0.0382 | -0.5123 | 0.0234 | 1.15 | 3.15 | 6,705.13 | -92.78 | -43.08 | -- | -72.93 | 32.50 | -- | -3,960.99 | -514.53 | 0.8927 | -2.79 | 2.38 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Darwin AG | -93.12bn | -93.12bn | 126.34m | 235.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -91.36 | -- | -99.91 | -- | -- | -- |
| Newron Pharmaceuticals SpA | 6.49m | -17.53m | 140.49m | 23.00 | -- | -- | -- | 21.65 | -0.9631 | -0.9631 | 0.3565 | -1.51 | 0.247 | -- | 3.46 | 282,123.30 | -66.74 | -37.10 | -109.83 | -43.98 | 93.37 | 91.72 | -270.17 | -270.48 | -- | -3.53 | 2.71 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Scancell Holdings Plc | 0.00 | -6.56m | 145.79m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Idorsia Ltd | 74.12m | -296.43m | 146.54m | 938.00 | -- | -- | -- | 1.98 | -1.68 | -1.68 | 0.3831 | -5.98 | 0.1271 | 0.236 | 56.93 | 79,021.32 | -50.85 | -46.72 | -123.79 | -53.84 | 77.71 | -- | -399.92 | -709.80 | 0.4153 | -21.55 | 206.68 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Vicore Pharma Holding AB | 8.44m | -15.91m | 150.27m | 29.00 | -- | 2.34 | -- | 17.80 | -1.72 | -1.72 | 0.9135 | 3.38 | 0.2045 | -- | 43.73 | 4,343,459.00 | -38.54 | -58.65 | -41.49 | -65.58 | -- | -- | -188.45 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Nanobiotix SA | 33.73m | -31.17m | 153.62m | 102.00 | -- | -- | -- | 4.55 | -0.763 | -0.763 | 0.8429 | -0.4594 | 0.57 | -- | 17.20 | 355,107.80 | -52.68 | -54.11 | -323.15 | -80.68 | -- | -- | -92.42 | -756.15 | -- | -2.42 | 1.87 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| Egetis Therapeutics AB (publ) | 6.41m | -23.95m | 155.35m | 33.00 | -- | 4.90 | -- | 24.22 | -1.07 | -1.07 | 0.2882 | 1.09 | 0.1425 | 23.00 | 3.61 | 2,933,333.00 | -48.67 | -33.02 | -61.23 | -36.46 | 85.48 | -- | -341.54 | -357.72 | 0.9808 | -19.71 | 0.2605 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Faron Pharmaceuticals Oy | 0.00 | -29.44m | 166.85m | 34.00 | -- | 129.93 | -- | -- | -0.3158 | -0.3158 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Xlife Sciences AG | 990.28k | 21.24m | 167.09m | 17.00 | 12.22 | 0.6083 | 5.28 | 168.73 | 2.38 | 2.38 | 0.1215 | 47.84 | 0.002 | -- | 0.2013 | 58,251.77 | 3.17 | -- | 3.98 | -- | 54.46 | -- | 1,579.69 | -- | -- | -- | 0.1313 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| hVIVO PLC | 72.12m | 19.54m | 167.68m | 274.00 | 8.72 | 3.89 | 7.24 | 2.32 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Hansa Biopharma AB | 15.34m | -53.03m | 168.49m | 135.00 | -- | -- | -- | 10.99 | -11.34 | -11.34 | 3.21 | -4.72 | 0.1794 | 34.61 | 1.25 | 1,127,321.00 | -62.01 | -47.96 | -86.68 | -56.12 | 53.43 | 64.18 | -345.73 | -835.04 | 2.44 | -41.44 | 1.50 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Devyser Diagnostics AB | 16.03m | -5.78m | 172.48m | 119.00 | -- | 6.09 | -- | 10.76 | -4.37 | -4.37 | 12.12 | 21.17 | 0.4019 | 1.97 | 5.29 | 1,677,966.00 | -14.51 | -8.97 | -16.40 | -10.15 | 80.00 | 80.14 | -36.11 | -23.91 | 3.81 | -- | 0.1492 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Sensorion SA | 0.00 | -22.04m | 178.53m | 61.00 | -- | 2.30 | -- | -- | -0.1048 | -0.1048 | 0.00 | 0.2777 | 0.00 | -- | -- | 0.00 | -36.68 | -35.12 | -47.21 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0274 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
Data as of Nov 22 2024. Currency figures normalised to Idorsia Ltd's reporting currency: Swiss Franc CHF
14.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 04 Nov 2024 | 10.29m | 5.44% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 5.35m | 2.83% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 5.02m | 2.65% |
| Astaris Capital Management LLPas of 04 Nov 2024 | 3.45m | 1.83% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 1.88m | 0.99% |
| Rossier, Mari & Associates AGas of 30 Sep 2024 | 1.12m | 0.59% |
| Pictet Asset Management SAas of 30 Jun 2024 | 348.36k | 0.18% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 278.40k | 0.15% |
| Charles Schwab Investment Management, Inc.as of 07 Nov 2024 | 278.01k | 0.15% |
| BlackRock Asset Management Deutschland AGas of 07 Nov 2024 | 272.71k | 0.14% |
More ▼
Data from 30 Sep 2024 - 04 Nov 2024Source: FactSet Research Systems Inc.
